Our study therefore presents an effort to address the mechanism of regulation of HER3 mediated under anti-HER2 treatment, which further supports the notion that inhibition of HER3, especially targeting HER2 mRNA might provide a novel therapeutic approach for HER2-targeted therapies in breast cancer. This evidence concerns the gene ERBB3 and breast carcinoma.